Yes, maraviroc doesn’t bind at the same spot as HIV. So HIV will mutate around that minor inconvenience. Leronlimab does, so as long as there is enough covering all the receptors, and R5, no where for HIV to go... IMO. The FDA has to see the importance of mdr4.

Also, Dr. Patterson showing that importance. When dormant infected cd4 cells become activated, the VL can spike, but as long as the receptors are covered with leronlimab, no where for the HIV to go.